Micell Technologies

Micell Technologies develops advanced biomedical devices focused on interventional cardiology. Its lead product, MiStent SES—a sirolimus-eluting absorbable polymer coronary stent—uses a proprietary supercritical fluid-based coating process to deliver precise and sustained release of sirolimus while minimizing long-term polymer exposure. The company holds an extensive patent portfolio covering its core technologies and has demonstrated clinical performance advantages over conventional permanent-polymer DES systems. The MiStent system has received CE Mark approval in Europe; further pipeline products include fully absorbable stents and drug-coated balloons using similar technology.